Table 5.
Seizure outcome studies of JME in the last 10 years (2013–2023).
| Study Design | Country (City) of Study |
No of Pts, n | Age, year, Mean ± SD/ Mean (Range) |
Female, n (%) |
Follow Up, year Mean ± SD/ Mean (Range) |
Seizure-Free, % | Ongoing Seizures, % | |
|---|---|---|---|---|---|---|---|---|
| Senf et al. 2013 [15] |
Single center | Germany (Berlin) | 66 | 58.9 ± 13.8 | 33 (50) | 44.6 ± 13.7 | 5 year: 59.1 | 40.9 |
| Schneider-von Podewils. 2014 [25] | Single center | Germany (Greifswald) | 33 | 52.3 ± 12.3 | 21 (63.3) | 37.8 ± 13.9 | >6 year: 54.5 | 45.5 |
| Syvertsen et al., 2014 [16] | Single center | Norway (Trondheim) | 40 | Median (range) 47 (35–81) |
25 (60) * | >20 | 5 year: 53 10 year: 33 |
47 |
| Höfler et al., 2014 [5] |
Single center | Austria (Salzburg) | 175 | Median (range) 38 (14–87) |
111 (63.4) | Median (range) 8 (2–38) | 1 year: 62 2 year: 53 >5 year: 15 |
38 |
| Desai et al., 2016 [18] |
Single center | India (Gujarat) |
73 | 27 (6–57) | 40 (54.8) | — | 2 year: 84.9 | 15.1 |
| Chowdhury et al., 2016 [6] | Single center | UK (Glasgow) |
186 | Median (range) 14 (2–32) | 108 (58) | Median (range) 14 (2–32) |
1 year: 92 | 8 |
| Cação et al., 2018 [26] |
Multi-center | UK (London, Chalfont) | 240 | 38 ± 11.7 | 146 (52.1) | 21.8 (1–60) | 1 year: 47.5 | 50.4 |
| Uchida et al., 2018 [27] |
Single center | Brazil (São Paulo) |
42 | 28.1 ± 11.1 # 32.9 ± 10.7 |
30 (71.4) | 8.2 ± 5.0 | 31 § | 69 |
| Zhang et al., 2019 [17] |
Single center | China (Chengdu) |
105 | 21.5 ± 5.3 | 57 (54.3) | 47.9 ± 7.2 | 1 year: 64.8 3 year: 29.5 5 year: 14.6 |
35.2 |
| Chen et al., 2020 [28] |
Single center | China (Xiamen) |
63 | 20.4 ± 6.9 | 30 (47.6) | — | 5 year: 63.5 | 36.5 |
| Viswanathan et al., 2021 [21] | Single center | India (Karnataka) |
56 | 14.5 ± 5.1 | 30 (53.6) | 10 year | 10 year: 60.7 @ | 39.3 |
| Pietrafusa et al., 2021 [13] | Single center | Italy (Apulia) |
61 | 37.6 ± 12.3 | 61 (65.6) | 28.9 ± 8.2 | 5 year: 65.5 | 34.5 |
| Asadi-Pooya et al., 2022 [20] | Single center | Iran (Shiraz) |
135 | 35 ± 8 | 92 (68.1) | 11 ± 2 | 1 year: 39.3 | 60.7 |
| Cerulli Irelli et al., 2022 [24] |
Single center | Italy (Rome) |
113 | Median (IOR) 64 (17–91) |
78 (69) | Median (IOR) 17 (9.5–27) |
2 year: 81.4 4 year: 67.3 |
18.6 |
| Current study | Single center | Taiwan (Taoyuan) | 49 | 27.6 ± 8.9 | 51 (25) | 11.4 ± 9.3 | 1 year: 49 | 51 |
* This study enrolled 42 patients with JME, and 25 (60%) of them were female. A subset of 40 underwent seizure outcome analysis. # The average ages (± SD) of JME patients with or without eye-closure sensitivity were 28.1 ± 11.1 and 32.9 ± 10.7, respectively. § The definition of seizure-free period was not reported. @ Patients were considered to have controlled seizures when they had <1 GTCS/year and no/very rare non-disabling myoclonia at the end of 10 years duration of epilepsy. —: not explicitly reported. JME (juvenile myoclonic epilepsy); pts, patients; y, year; SD, standard deviation; IOR, interquartile range.